These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

629 related items for PubMed ID: 19762065

  • 1. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.
    Shah SS, Ketterling RP, Goetz MP, Ingle JN, Reynolds CA, Perez EA, Chen B.
    Hum Pathol; 2010 Jan; 41(1):103-6. PubMed ID: 19762065
    [Abstract] [Full Text] [Related]

  • 2. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ, Janjigian YY, Zaidinski M, Hedvat CV, Hameed MR, Tang LH, Hicks JB, Shah MA, Barbashina V.
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [Abstract] [Full Text] [Related]

  • 3. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization.
    Bethune GC, Veldhuijzen van Zanten D, MacIntosh RF, Rayson D, Younis T, Thompson K, Barnes PJ.
    Histopathology; 2015 Dec; 67(6):880-7. PubMed ID: 25913507
    [Abstract] [Full Text] [Related]

  • 4. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ, Wang BB, Chang CS, Chen TH, Yeh KT, Lee DJ, Yin PL, Chen M.
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.
    Baehner FL, Achacoso N, Maddala T, Shak S, Quesenberry CP, Goldstein LC, Gown AM, Habel LA.
    J Clin Oncol; 2010 Oct 01; 28(28):4300-6. PubMed ID: 20697093
    [Abstract] [Full Text] [Related]

  • 8. Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis.
    Dieci MV, Barbieri E, Bettelli S, Piacentini F, Omarini C, Ficarra G, Balduzzi S, Dominici M, Conte P, Guarneri V.
    J Clin Pathol; 2012 Jun 01; 65(6):503-6. PubMed ID: 22389512
    [Abstract] [Full Text] [Related]

  • 9. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH, Lim AS, Thike AA, Tien SL, Tan PH.
    Arch Pathol Lab Med; 2016 Feb 01; 140(2):140-7. PubMed ID: 26910218
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Oestrogen receptor/progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer: a 9-year study at Princess Noorah Oncology Center, Saudi Arabia.
    Satti MB.
    Histopathology; 2011 Sep 01; 59(3):537-42. PubMed ID: 21668473
    [Abstract] [Full Text] [Related]

  • 13. Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17.
    Vranic S, Teruya B, Repertinger S, Ulmer P, Hagenkord J, Gatalica Z.
    Cancer; 2011 Jan 01; 117(1):48-53. PubMed ID: 20803611
    [Abstract] [Full Text] [Related]

  • 14. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K, Tantravahi U, Lomme MM, Pasquariello T, Steinhoff M, Sung CJ.
    Breast Cancer Res Treat; 2016 Jun 01; 157(3):405-11. PubMed ID: 27180259
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
    Stålhammar G, Farrajota P, Olsson A, Silva C, Hartman J, Elmberger G.
    Ann Diagn Pathol; 2015 Aug 01; 19(4):203-10. PubMed ID: 25921313
    [Abstract] [Full Text] [Related]

  • 18. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
    Woo JW, Lee K, Chung YR, Jang MH, Ahn S, Park SY.
    Hum Pathol; 2020 Apr 01; 98():10-21. PubMed ID: 32027910
    [Abstract] [Full Text] [Related]

  • 19. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
    Akhdar A, Bronsard M, Lemieux R, Geha S.
    Ann Pathol; 2011 Dec 01; 31(6):472-9. PubMed ID: 22172120
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.